Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir/Velpatasvir FDC in Chronic HCV
NCT02671500Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2016
- Primary completion
- Jan 2018
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of velpatasvir in hepatitis C (HCV), sponsored by Gilead Sciences. Primary endpoints: Sustained Virologic Response 12 Weeks After Discontinuation of Therapy and Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event up to 12 weeks. Started Apr 2016; status: completed.
02
Drugs
velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02671500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02671500.